Bolt Biotherapeutics Secures $120M Private Placement, With Potential Additional $60M From Warrant Exercise To Fund Operations Into 2028
Concurrent with the acquisition, Bolt entered into a definitive agreement for a private placement financing to raise $120 million in gross proceeds, for the purchase of 13,995.311 shares of Series D non-voting
Bolt Biotherapeutics raised $120 million to keep running its business. This money should help them operate until 2028 without needing more funding soon.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.